Pneumonia Treatment — Evidence-Based Antibiotic and Clinical Management Guide — Cost, Top Hospitals & Success Rates | MyMedicPlus

Pneumonia is an acute infection of the lower respiratory tract causing inflammation of the lung parenchyma, typically resulting in alveolar consolidation and impaired gas exchange. It is the leading infectious cause of hospitalisation and death worldwide, responsible for over 2.5 million deaths annually across all age groups and accounting for the majority of sepsis cases requiring ICU admission.

Pneumonia is classified primarily by the setting of acquisition:

• Community-acquired pneumonia (CAP): Infection developing outside of healthcare facilities, or within 48 hours of hospital admission in a non-institutionalised patient. The most common causative organism globally remains Streptococcus pneumoniae.
• Hospital-acquired pneumonia (HAP): Pneumonia developing more than 48 hours after hospital admission, not incubating at admission. Associated with drug-resistant organisms including Pseudomonas aeruginosa, MRSA, and Enterobacteriaceae.
• Ventilator-associated pneumonia (VAP): A subgroup of HAP occurring more than 48–72 hours after endotracheal intubation, carrying mortality rates of 20–50% in critically ill patients.
• Aspiration pneumonia: Caused by inhalation of oropharyngeal flora in patients with impaired swallowing or consciousness — common in stroke, epilepsy, and anaesthesia.

Causative organisms in CAP include Streptococcus pneumoniae (most common), Haemophilus influenzae, atypicals (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila), viral pathogens (influenza A/B, SARS-CoV-2, RSV), and rarely anaerobes. The causative organism is identified in only 40–60% of CAP cases even with comprehensive diagnostic workup.

Effective treatment depends critically on accurate severity assessment, empirical antibiotic selection guided by local resistance patterns and clinical risk factors, and timely administration — with evidence strongly supporting antibiotic delivery within 4 hours of presentation in hospitalised CAP.

Treatment strategy differs substantially by pneumonia subtype, host immune status, and organism epidemiology:

• Typical CAP (S. pneumoniae, H. influenzae): Presents with abrupt onset of fever, productive cough, pleuritic chest pain, and lobar consolidation on chest X-ray. Streptococcus pneumoniae remains the commonest identifiable CAP pathogen globally. Beta-lactam antibiotics are the cornerstone of treatment, with penicillin sensitivity guided by local minimum inhibitory concentration data.
• Atypical CAP (Mycoplasma, Chlamydophila): Presents with more insidious onset, lower fever, prominent dry cough, extrapulmonary features (rash, haemolytic anaemia, hepatitis), and bilateral interstitial infiltrates. Macrolides (azithromycin, clarithromycin) or doxycycline are effective; beta-lactams are not.
• Legionella pneumophila (Legionnaires' Disease): A severe CAP requiring ICU admission in 10–20% of cases, associated with pontine hyponatraemia, elevated LDH, lymphopenia, and urinary antigen positivity. Fluoroquinolones (levofloxacin) or azithromycin are treatments of choice; beta-lactams alone are inadequate.
• Viral Pneumonia (Influenza, COVID-19): Influenza pneumonia warrants oseltamivir regardless of symptom duration in hospitalised patients. COVID-19 pneumonia (SARS-CoV-2) is managed with dexamethasone 6 mg daily (in patients requiring supplemental oxygen, per RECOVERY trial), remdesivir in appropriate patients, and baricitinib or tocilizumab for those with escalating oxygen requirements.
• HAP/VAP: Empirical anti-pseudomonal beta-lactam (piperacillin-tazobactam, meropenem, cefepime) ± anti-MRSA agent (vancomycin, linezolid), guided by local antibiogram and patient risk factors for resistant organisms. De-escalation to targeted therapy at 48–72 hours based on culture results is critical to limit resistance selection.
• Pneumocystis Pneumonia (PCP): Caused by Pneumocystis jirovecii in immunocompromised hosts (HIV with CD4 <200/μL, solid organ transplant, long-term steroids). Treated with high-dose co-trimoxazole (trimethoprim-sulfamethoxazole); adjunctive corticosteroids in HIV-related PCP with PaO₂ <70 mmHg reduce mortality.

Pneumonia severity determines whether a patient can be safely managed in the community, requires general ward admission, or needs high-dependency/ICU-level care. Two validated tools are routinely used:

CURB-65 Score (British Thoracic Society): Each criterion scores 1 point:

• C — Confusion (new acute disorientation)
• U — Urea >7 mmol/L
• R — Respiratory rate ≥30 breaths/minute
• B — Blood pressure systolic <90 mmHg or diastolic ≤60 mmHg
• 65 — Age ≥65 years

Score interpretation: 0–1: Low severity — outpatient treatment appropriate (30-day mortality ~1.5%). 2: Moderate severity — consider hospitalisation; short inpatient stay. 3–5: High severity — hospitalise urgently; consider ICU if score ≥4 (30-day mortality 22–28%).

Pneumonia Severity Index (PSI/PORT Score): A more complex 20-variable score (incorporating demographics, comorbidities, physical signs, and laboratory findings) that stratifies patients into five risk classes. PSI Class I–II: outpatient; Class III: brief observation; Class IV–V: hospitalise. PSI is more accurate than CURB-65 but less practical at the bedside without electronic calculation tools.

SMART-COP: An alternative score developed in Australia that predicts need for intensive respiratory or vasopressor support (IRVS) with high sensitivity, including SpO₂, multilobar involvement, albumin, tachycardia, confusion, oxygenation, pH, and blood pressure.

Additional eligibility considerations: Immunocompromised patients (HIV, transplant, haematological malignancy, biologics) require a lower threshold for hospitalisation and broader diagnostic workup regardless of CURB-65 score. Nursing home residents with CAP should generally be managed as HAP given increased risk of drug-resistant organisms.

Mild CAP (CURB-65 0–1) — Outpatient: Amoxicillin 500 mg three times daily orally for 5 days is first-line in the UK (BTS/NICE 2019 guidance) and preferred in most European guidelines where pneumococcal beta-lactam resistance remains low. If atypical organism (Mycoplasma, Chlamydophila) is suspected on clinical grounds (younger patient, dry cough, bilateral infiltrates, extrapulmonary features), doxycycline 200 mg loading dose then 100 mg twice daily or clarithromycin 500 mg twice daily are alternatives. In penicillin allergy, doxycycline or clarithromycin are appropriate substitutes.

Moderate CAP (CURB-65 2) — Hospital Ward: Co-amoxiclav 625 mg three times daily orally (or 1.2 g IV TDS if unable to take orally) plus clarithromycin 500 mg twice daily provides dual-spectrum coverage against typical and atypical organisms. IV amoxicillin-clavulanate plus a macrolide is a standard choice where oral absorption is unreliable.

Severe CAP (CURB-65 3–5) — Hospitalise/ICU: IV dual therapy is mandatory. Piperacillin-tazobactam 4.5 g three times daily IV plus azithromycin 500 mg once daily IV or co-amoxiclav 1.2 g TDS IV plus clarithromycin 500 mg BD IV. Fluoroquinolone monotherapy (levofloxacin 500 mg IV OD) is an alternative for penicillin-allergic patients with severe CAP.

MRSA-risk CAP (post-influenza, cavitary pneumonia, prior MRSA colonisation, IV drug use): Add vancomycin (dose-targeted to AUC/MIC 400–600 mg·h/L per ASHP/IDSA 2020 guidelines, typically 15–20 mg/kg IV every 8–12 hours) or linezolid 600 mg IV/oral twice daily (which achieves superior lung parenchymal concentrations versus vancomycin).

Legionella pneumophila: Levofloxacin 500–750 mg once daily IV/oral for 5–10 days is preferred for severe Legionnaire's disease. Azithromycin 500 mg daily for 5 days is adequate for mild-to-moderate disease. Beta-lactams alone are ineffective against Legionella.

HAP/VAP: Empirical anti-pseudomonal therapy: piperacillin-tazobactam 4.5 g QDS, meropenem 1–2 g TDS, or cefepime 2 g TDS ± vancomycin if MRSA risk factors exist. Cultures (BAL, protected specimen brush) should be obtained before antibiotic initiation whenever possible; de-escalate at 48–72 hours based on sensitivities. Duration of 7 days is supported by clinical trials (JAMA 2003) for most patients with clinical improvement.

Antibiotic duration: 5 days for mild–moderate CAP (BTS/NICE 2019), with extension to 7 days only if clinical response is inadequate. Severe CAP: 7–10 days. Legionella: 7–10 days (up to 21 days in immunocompromised). HAP/VAP: 7 days standard. Serial CRP or procalcitonin-guided de-escalation reduces unnecessary antibiotic exposure.

Appropriately treated pneumonia has excellent outcomes, particularly in younger patients without comorbidities presenting with low-severity CAP.

Clinical resolution timeline: Most patients with mild-to-moderate CAP treated with appropriate antibiotics become afebrile within 48–72 hours. Cough may persist for 2–4 weeks as airway epithelial repair occurs. Radiological clearance typically lags 4–8 weeks behind clinical improvement, and this does not indicate treatment failure in the absence of clinical deterioration. Elderly patients and those with co-morbidities take longer to achieve clinical and radiological resolution.

Mortality reduction with timely antibiotic initiation: Multiple observational studies demonstrate that initiating antibiotics within 4 hours of pneumonia diagnosis reduces in-hospital mortality. This has been incorporated into quality benchmarks in the UK (CQUIN targets) and US (CMS quality measures). Concurrent fluid resuscitation in patients with septic physiology (MAP <65 mmHg, lactate >2 mmol/L) further reduces mortality from severe pneumonia-associated sepsis.

Outcomes by CURB-65 severity: CURB-65 0–1: 30-day mortality approximately 1.5% with outpatient therapy. CURB-65 2: Mortality 9% with hospitalisation. CURB-65 3: Mortality 17%. CURB-65 4–5: Mortality 22–28% even with ICU-level care, highlighting the importance of early recognition and aggressive intervention.

COVID-19 pneumonia outcomes: The RECOVERY trial demonstrated dexamethasone 6 mg daily for up to 10 days reduced 28-day mortality by 35% in mechanically ventilated patients with COVID-19 pneumonia and by 20% in those requiring supplemental oxygen — one of the most impactful trial results in modern critical care medicine.

Prevention via vaccination: Pneumococcal vaccination (PCV13 followed by PPSV23) reduces risk of invasive pneumococcal disease by 50–70% in high-risk adults. Annual influenza vaccination reduces influenza-attributable pneumonia hospitalisations by 30–50% in elderly populations.

The risks of pneumonia treatment span both disease-related complications and antibiotic-related adverse effects.

Pneumonia complications:

• Parapneumonic effusion and empyema: Occur in 20–40% of hospitalised CAP; empyema (infected pleural collection) requires drainage (intercostal drain ± intrapleural fibrinolytics) and prolonged antibiotic therapy
• Lung abscess: Cavitation and pus collection, most commonly from aspiration of anaerobic oral flora; requires 4–6 weeks of antibiotics including anaerobic cover (co-amoxiclav or metronidazole)
• Respiratory failure: Hypoxaemic respiratory failure requiring non-invasive ventilation (CPAP/BiPAP) or mechanical ventilation occurs in 5–10% of hospitalised CAP
• Septic shock: 5–7% of hospitalised CAP; associated with 30–40% mortality despite ICU management
• ARDS: Acute respiratory distress syndrome develops in a subset of severe pneumonia patients, particularly with bilateral infiltrates and PaO₂/FiO₂ <200

Antibiotic adverse effects:

• Beta-lactams (amoxicillin, co-amoxiclav): Diarrhoea (3–8%), rash (1–5%), anaphylaxis (rare, 0.01%)
• Macrolides (clarithromycin, azithromycin): GI intolerance, QTc interval prolongation (particularly in combination with other QT-prolonging agents), transient hepatotoxicity; cardiac death risk with azithromycin has been flagged in patients with pre-existing cardiac disease
• Fluoroquinolones (levofloxacin): Tendinopathy (Achilles tendon rupture), peripheral neuropathy, QTc prolongation, seizures (rare), Clostridioides difficile infection (CDI). Restricted to appropriate indications by regulatory authorities due to safety concerns
• Vancomycin: Nephrotoxicity (dose-dependent), ototoxicity (rare), infusion-related ‘red man syndrome’ (flushing, erythema — rate-related, not IgE-mediated)
• Clostridioides difficile colitis: Risk with all antibiotics, particularly clindamycin, fluoroquinolones, cephalosporins, and broad-spectrum penicillins; presents as watery diarrhoea during or within 8 weeks of antibiotic use

Follow-up care after pneumonia is guided by disease severity, underlying aetiology, host factors, and treatment response. It serves to confirm resolution, investigate predisposing conditions, and prevent recurrence.

Clinical switch-to-oral and discharge criteria: Intravenous antibiotic therapy in hospitalised patients can be safely switched to oral equivalents when all of the following criteria are met (BTS 2015):

• Temperature below 37.8°C for at least 24 hours
• Heart rate below 100 beats per minute
• Oxygen saturation above 94% on room air (or on prior domiciliary oxygen)
• Systolic blood pressure above 90 mmHg without vasopressor support
• Tolerating oral fluids and medications
• No other clinical reason requiring continued inpatient care

Early oral switch reduces hospitalisation duration by 1–2 days with no increase in treatment failure rates, as demonstrated in the FAST-CAP and CAPTIME trials.

Follow-up chest X-ray (CXR): For most patients, resolution of consolidation on CXR is expected by 4–6 weeks (longer in elderly). A repeat CXR at 6 weeks post-discharge is recommended in UK guidelines for patients aged ≥50 or with risk factors for lung malignancy (smokers, persistent symptoms), to exclude an underlying endobronchial lesion presenting as post-obstructive pneumonia. Persistent consolidation beyond 8 weeks warrants CT thorax and bronchoscopy.

Microbiological review: Culture results (blood cultures, sputum, BAL, urinary antigen for pneumococcus and Legionella) should be reviewed to enable antibiotic de-escalation or pathogen-targeted switching, particularly important in HAP/VAP where resistant organism selection is a concern.

Pneumococcal and influenza vaccination: All eligible patients (those aged ≥65, immunocompromised, or with chronic respiratory/cardiac/renal/liver disease) should be offered vaccination at or shortly after discharge if not already immunised.

NHSN surveillance: HAP and VAP in healthcare settings are subject to National Healthcare Safety Network (NHSN) surveillance criteria — a diagnosis requires pneumonia developing more than 48 hours post-admission with specific radiological and clinical criteria, to distinguish true HAP from new CAP, heart failure, or aspiration.

The economic impact of pneumonia spans direct healthcare costs (antibiotics, hospitalisation, investigations) and indirect costs (lost productivity, long-term sequelae). Pneumonia is one of the most costly infectious diseases globally in terms of healthcare expenditure.

Outpatient CAP: A 5-day course of amoxicillin costs approximately £1.50–$4 USD in generic form — among the most cost-effective antibiotic regimens available. Doxycycline and clarithromycin are similarly inexpensive generics. Total outpatient management cost including GP consultation, CXR, and pharmacy is typically £100–£250 in the UK and $200–$600 USD in the US.

Hospitalised CAP: Inpatient pneumonia treatment carries substantially higher costs. Average hospitalisation for moderate CAP in the UK costs the NHS approximately £2,000–£4,000 per episode (including diagnostic tests, IV antibiotics, oxygen, nursing, and a 3–5 day stay). In the United States, the mean hospital charge for pneumonia admission (without ventilation) is $12,000–$20,000 USD. ICU admission for severe CAP with respiratory failure multiplies this to $40,000–$100,000+.

IV antibiotic costs: Piperacillin-tazobactam (4.5 g TDS): approximately £15–25 per day at NHS contract price. Vancomycin: £5–10 per day in generic form. Linezolid 600 mg BD: £200–£400 per day branded (generic considerably cheaper). Meropenem 1 g TDS: £15–£30 per day. Drug costs represent only 10–15% of total hospitalisation expense; ward and critical care bed costs dominate.

VAP-related costs: VAP adds an estimated 4–14 extra ICU days per episode, translating to £10,000–£40,000 USD in additional costs per VAP episode in high-income countries, underscoring the importance of VAP prevention bundles (daily sedation holds, head-of-bed elevation, oral chlorhexidine, sub-glottic suctioning).

Vaccination cost-effectiveness: Pneumococcal vaccination programmes are highly cost-effective in elderly populations, with cost-per-QALY gained well below accepted thresholds in the UK (<£20,000) and US (<$50,000), making them among the best-value public health investments for respiratory disease prevention.

Supportive care: Antipyretics (paracetamol/acetaminophen) for fever and myalgia; adequate hydration (oral or IV); supplemental oxygen titrated to SpO₂ 94–98% (88–92% in COPD); sitting upright to optimise respiratory mechanics; chest physiotherapy in patients with retained secretions (particularly post-stroke or neuromuscular disease). Supportive care is the primary treatment for viral pneumonia where no antiviral exists, and is the cornerstone alongside antivirals for influenza and COVID-19.

Non-invasive ventilation (NIV/BiPAP): For hypercapnic respiratory failure complicating pneumonia in COPD patients, BiPAP (bilevel positive airway pressure) reduces intubation rates and mortality. High-flow nasal oxygen (HFNO) at 40–60 L/min in hypoxaemic CAP without hypercapnia has been shown in the FLORALI trial to reduce intubation rates and 90-day mortality versus standard face-mask oxygen.

Corticosteroids as adjunct in CAP: Prednisolone or dexamethasone as adjunctive therapy in hospitalised CAP has been evaluated in multiple RCTs and meta-analyses. Current evidence (RECOVERY-CAP) does not support routine adjunctive steroids in non-COVID CAP outside of septic shock (where hydrocortisone is indicated). In COVID-19 pneumonia requiring oxygen, dexamethasone 6 mg daily is standard of care.

Primary prevention — vaccination:

• Pneumococcal conjugate vaccine (PCV15, PCV20): Recommended for all adults ≥65 and younger adults with chronic lung disease, heart disease, diabetes, immunocompromise, asplenia, CSF leak, or cochlear implant
• Annual influenza vaccine: Reduces influenza-associated pneumonia; recommended for all healthcare workers and high-risk adults
• COVID-19 mRNA vaccines: Substantially reduce severe COVID-19 pneumonia, ICU admission, and death
• RSV vaccines (RSVPreF3, mRNA-1345): Newly approved for adults ≥60; reduce RSV-associated lower respiratory tract disease and hospitalisation

VAP prevention bundles: Evidence-based VAP bundle elements — 30–45° head-of-bed elevation, daily spontaneous breathing trials, daily sedation interruption, oral chlorhexidine decontamination, sub-glottic secretion drainage, and selective digestive decontamination in high-risk ICU populations — reduce VAP incidence by 50–70% in compliant centres.